Oxford University Press

SHERPA: Yellow

People

  1. De Angelis
    De Angelis
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Mellinghoff
    Mellinghoff
  5. Rosenblum
    Rosenblum
  6. Shuman
    Shuman
  7. Dunkel
    Dunkel
  8. Karajannis
    Karajannis
  9. Saltz
    Saltz
  10. Souweidane
    Souweidane

Groups

  1. Department of Medicine (1985)
  2. Solid Tumor Oncology Division (1617)
  3. GSK Faculty (763)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)
  7. Department of Pathology and Laboratory Medicine (414)
  8. Gastrointestinal Oncology Service (385)
  9. Genitourinary Oncology Service (364)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2095)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (89)
  5. Editorial (80)
  6. Guidelines (36)
  7. Correspondence (24)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (9)
Groups
  1. Department of Medicine (1985)
  2. Solid Tumor Oncology Division (1617)
  3. GSK Faculty (763)
  4. Survivorship Research (636)
  5. Population Sciences Research Program (613)
  6. Epidemiology and Biostatistics (463)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Marc Rosenblum (87)
  6. Stewart Shuman (87)

More People

Years
  1. 2025 (83)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1668)
  2. Neuro-Oncology (845)
  3. JNCI: Journal of the National Cancer Institute (482)
  4. Nucleic Acids Research (209)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (105)

More Publications

Results (4630)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study
    Meeting Abstract

    Shiu, K. K.; André, T.; Kim, T. W.; Vittrup Jensen, B.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; Alcaide-Garcia, J.; Gibbs, P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
    Meeting Abstract

    Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Oh, D. Y.; Banerjee, S.; Gonzalez Martin, A.; Jung, K. H.; Lugowska, I.; Manso, L. M.; Manzano, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/ paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
    Meeting Abstract

    Eskander, R. N.; Sill, M.; Miller, A.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M. S.; Canturia, G.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)
    Meeting Abstract

    Liu, J. F.; Brady, M.; Matulonis, U. A.; Miller, A.; Kohn, E. C.; Swisher, E.; Tew, W.; Cloven, N.; Muller, C.; Bender, D.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)
    Meeting Abstract

    Sridhar, S.; O'Donnell, P. H.; Flaig, T. W.; Rosenberg, J. E.; Hoimes, C. J.; Milowsky, M. I.; Srinivas, S.; George, S.; McKay, R. R.; Petrylak, D. P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Consensus views on research priorities for cancer survivorship in older adulthood: A Delphi study
    Meeting Abstract

    Drury, A.; O'Brien, A.; O'Connell, L.; Cosgrave, S.; Hannan, M.; Smyth, C.; Fessele, K.; Sheehan, S.; Harkin, M.; Rogers, L.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial
    Meeting Abstract

    Bardia, A.; Jhaveri, K.; Im, S. A.; Pernas Simon, S.; De Laurentiis, M.; Wang, S.; Martinez, N.; Santos Borges, G.; Cescon, D. W.; Hattori, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Novel therapeutic opportunities in metaplastic breast cancer
    Meeting Abstract

    Pareja, F.; Gazzo, A.; Dopeso, H.; Brown, D.; Selenica, P.; Zhu, Y.; Blanco Heredia, J.; Gusain, L.; Pei, X.; Marra, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from IMpassion031
    Meeting Abstract

    Harbeck, N.; Duan, C.; DuPree, K.; Chang, C. W.; Barrios, C. H.; Zhang, H. A.; Saji, S.; Jung, K. H.; Telli, M. L.; Liste Hermoso, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • CDC7 inhibition constrains lineage plasticity and prevents resistance and neuroendocrine transformation in the lung and prostate
    Meeting Abstract

    Quintanal-Villalonga, Á.; Zaidi, S.; Karthaus, W. R.; Zhan, Y. A.; Shafer, M.; Qiu, J.; de Stanchina, E.; Haffner, M. C.; Sawyers, C. L.; Rudin, C. M.
    Annals of Oncology (2023)

    Fulltext@MSK | Save